COMP <GO>
TEVA vs UNH // GROSS PROFIT MARGIN
Teva Pharmaceutical Industries Limited (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: TEVA 5
— UNH 10
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
gross-margins
51.80%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 51.80% | 88.57% | -36.77 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 11.47% | -2.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 16.4x | +4.35 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 6.48% | -4.67 | UNH | /fcf-yield <GO> |
| Operating Margin | 12.50% | 4.82% | +7.68 | TEVA | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 3.14% | +5.06 | TEVA | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 6.46% | -2.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 3.12 | -2.10 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TEVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.7 | 56.0 | +7.63 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 17.1x | +14.81 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $364.66B | -$316.33B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | UNH REV | TEVA GROSS % | UNH GROSS % | TEVA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $447.57B | 51.8% | 88.7% | $872.4M | $16.07B |
| FY 2024 | $16.54B | $400.28B | 48.7% | 88.3% | $502.5M | $20.70B |
| FY 2023 | $15.85B | $371.62B | 44.0% | 89.6% | $654.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
UNH // BETA 0.33